Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | UBE2N | P61088 | 1/20 | 0.81 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | FDPS | P14324 | 1/20 | 0.72 |
| ▸ | NISCH | Q9Y2I1 | 7/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidocarb SCHEMBL29504223 | 0.99 | ACHE (1.00) | ACHEUBE2NPAX8LMNAFDPS | |
| Imidocarb SCHEMBL8019509 | 0.99 | ACHE (1.00) | ACHEUBE2NPAX8LMNAFDPS | |
| Imidocarb SCHEMBL203921 | 0.99 | ACHE (1.00) | ACHEUBE2NPAX8LMNAFDPS | |
| Imidocarb SCHEMBL27988892 | 0.97 | ACHE (0.97) | ACHEUBE2NPAX8LMNAFDPS | |
| Imidocarb SCHEMBL635410 | 0.97 | ACHE (0.97) | ACHEUBE2NPAX8LMNAFDPS | |
| Imidocarb SCHEMBL1142887 | 0.97 | ACHE (0.97) | ACHEUBE2NPAX8LMNAFDPS | |
| SCHEMBL17086987 | 0.97 | ACHE (0.97) | ACHEUBE2NPAX8LMNAFDPS | |
| SCHEMBL12869957 | 0.96 | ACHE (0.94) | ACHEUBE2NPAX8LMNAFDPS | |
| SCHEMBL16275222 | 0.94 | ACHE (0.92) | ACHEUBE2NPAX8LMNAFDPS | |
| Hydrochloric Acid SCHEMBL1143126 | 0.94 | ACHE (0.92) | ACHEUBE2NPAX8LMNAFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680307-B2 | Complexes and method for synthesis of group 6 organometallics grafted on anions, and use thereof in an olefin metathesis method | IFP Energies Nouvelles (FR) | 2014-03-25 | — | — | US | disclosed |
| US-8680306-B2 | Complexes and method for synthesis of group 6 organometallics, and use thereof in an olefin metathesis method | IFP Energies Nouvelles (FR) | 2014-03-25 | — | — | US | disclosed |
| US-20110098496-A1 | NOVEL COMPLEXES AND METHOD FOR SYNTHESIS OF GROUP 6 ORGANOMETALLICS, AND USE THEREOF IN AN OLEFIN METATHESIS METHOD | IFP Energies Nouvelles (FR) | 2011-04-28 | — | — | US | disclosed |
| US-20110098497-A1 | NOVEL COMPLEXES AND METHOD FOR SYNTHESIS OF GROUP 6 ORGANOMETALLICS GRAFTED ON ANIONS, AND USE THEREOF IN AN OLEFIN METATHESIS METHOD | IFP Energies Nouvelles (FR) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098496-A1 | NOVEL COMPLEXES AND METHOD FOR SYNTHESIS OF GROUP 6 ORGANOMETALLICS, AND USE THEREOF IN AN OLEFIN METATHESIS METHOD | BHMT2, BHMT, TST | ACHE 1740/4885UBE2N 619/4885PAX8 1733/4885 |
| US-20110098497-A1 | NOVEL COMPLEXES AND METHOD FOR SYNTHESIS OF GROUP 6 ORGANOMETALLICS GRAFTED ON ANIONS, AND USE THEREOF IN AN OLEFIN METATHESIS METHOD | HAO2, AOC3, AOC2 | ACHE 1026/4885UBE2N 2386/4885PAX8 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.